TY - JOUR
T1 - Amphiregulin in intestinal acute graft-versus-host disease
T2 - a possible diagnostic and prognostic aid
AU - Amin, Khalid
AU - Yaqoob, Usman
AU - Schultz, Brittney
AU - Vaughn, Byron P.
AU - Khoruts, Alexander
AU - Howard, Justin R.
AU - DeFor, Todd E.
AU - Forster, Colleen
AU - Meyer, Carolyn
AU - Gandhi, Isha
AU - Weisdorf, Daniel J.
AU - Rashidi, Armin
AU - MacMillan, Margaret L.
AU - Blazar, Bruce R.
AU - Panoskaltsis-Mortari, Angela
AU - Holtan, Shernan G.
N1 - Funding Information:
Acknowledgements This study was funded by the Masonic Cancer Center Pilot Grant program (SGH), Marrow on the Move (SGH), and R37 AI 34495 (BRB). SGH is supported by a Women’s Early Research Career award funded by the University of Minnesota Department of Medicine. We would like to acknowledge Michael Ehrhardt of the UMN Cytokine Reference Laboratory for technical assistance.
Publisher Copyright:
© 2018, United States & Canadian Academy of Pathology.
PY - 2019/4/1
Y1 - 2019/4/1
N2 - Amphiregulin, a weak epidermal growth factor receptor agonist, is elevated, while epidermal growth factor, a strong epidermal growth factor receptor agonist, is low in the blood of patients with severe acute graft-versus-host disease. However, the tissue expression and function of these epidermal growth factor receptor ligands in acute graft-versus-host disease target organs is unknown. We compared by immunohistochemistry expression of amphiregulin and epidermal growth factor in archived, formalin-fixed, paraffin-embedded intestinal tissues of 48 patients with biopsy-proven gastrointestinal acute graft-versus-host disease to 3 groups: (1) 10 non-hematopoietic cell transplant normal controls, (2) 11 patients with newly diagnosed ulcerative colitis (ulcerative colitis), (3) 8 patients with a clinical diagnosis of acute graft-versus-host disease despite pathologically non-diagnostic biopsies, (4) and 10 cases of cytomegalovirus colitis. We used a semi-quantitative score of 0 (absent) through 3 (strong) to describe the intensity of immunohistochemical staining. We correlated serum and tissue amphiregulin and epidermal growth factor in patients with acute graft-versus-host disease. Gastrointestinal amphiregulin was significantly lower in acute graft-versus-host disease biopsies (median score 1), ulcerative colitis (median score 1.5), and cytomegalovirus colitis (median score 1) than in normal colon (median score 2, p = 0.004, p = 0.03, p = 0.009 respectively). Amphiregulin expression in was low in 74% of acute graft-versus-host disease cases with or without significant apoptosis. Patients with acute graft-versus-host disease exhibiting the pattern of high gastrointestinal amphiregulin but low serum amphiregulin (n = 14) had the best 1-year survival at 71%, but patients with high serum amphiregulin had poorer survival (<30%) regardless of gastrointestinal amphiregulin expression. Overall, our results lead to the hypothesis that amphiregulin is released into the circulation from damaged intestinal epithelium and stroma, although contributions from other cellular sources are likely. Low gastrointestinal amphiregulin expression by immunohistochemistry may be further studied for its utility in the pathologic acute graft-versus-host disease diagnosis without classic apoptotic changes.
AB - Amphiregulin, a weak epidermal growth factor receptor agonist, is elevated, while epidermal growth factor, a strong epidermal growth factor receptor agonist, is low in the blood of patients with severe acute graft-versus-host disease. However, the tissue expression and function of these epidermal growth factor receptor ligands in acute graft-versus-host disease target organs is unknown. We compared by immunohistochemistry expression of amphiregulin and epidermal growth factor in archived, formalin-fixed, paraffin-embedded intestinal tissues of 48 patients with biopsy-proven gastrointestinal acute graft-versus-host disease to 3 groups: (1) 10 non-hematopoietic cell transplant normal controls, (2) 11 patients with newly diagnosed ulcerative colitis (ulcerative colitis), (3) 8 patients with a clinical diagnosis of acute graft-versus-host disease despite pathologically non-diagnostic biopsies, (4) and 10 cases of cytomegalovirus colitis. We used a semi-quantitative score of 0 (absent) through 3 (strong) to describe the intensity of immunohistochemical staining. We correlated serum and tissue amphiregulin and epidermal growth factor in patients with acute graft-versus-host disease. Gastrointestinal amphiregulin was significantly lower in acute graft-versus-host disease biopsies (median score 1), ulcerative colitis (median score 1.5), and cytomegalovirus colitis (median score 1) than in normal colon (median score 2, p = 0.004, p = 0.03, p = 0.009 respectively). Amphiregulin expression in was low in 74% of acute graft-versus-host disease cases with or without significant apoptosis. Patients with acute graft-versus-host disease exhibiting the pattern of high gastrointestinal amphiregulin but low serum amphiregulin (n = 14) had the best 1-year survival at 71%, but patients with high serum amphiregulin had poorer survival (<30%) regardless of gastrointestinal amphiregulin expression. Overall, our results lead to the hypothesis that amphiregulin is released into the circulation from damaged intestinal epithelium and stroma, although contributions from other cellular sources are likely. Low gastrointestinal amphiregulin expression by immunohistochemistry may be further studied for its utility in the pathologic acute graft-versus-host disease diagnosis without classic apoptotic changes.
UR - http://www.scopus.com/inward/record.url?scp=85056452262&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056452262&partnerID=8YFLogxK
U2 - 10.1038/s41379-018-0170-z
DO - 10.1038/s41379-018-0170-z
M3 - Article
C2 - 30425334
AN - SCOPUS:85056452262
SN - 0893-3952
VL - 32
SP - 560
EP - 567
JO - Modern Pathology
JF - Modern Pathology
IS - 4
ER -